U.S. markets open in 9 hours 21 minutes
  • S&P Futures

    3,794.00
    +3.50 (+0.09%)
     
  • Dow Futures

    30,808.00
    -20.00 (-0.06%)
     
  • Nasdaq Futures

    13,031.25
    +45.75 (+0.35%)
     
  • Russell 2000 Futures

    2,140.00
    -7.30 (-0.34%)
     
  • Crude Oil

    53.35
    +0.37 (+0.70%)
     
  • Gold

    1,849.10
    +8.90 (+0.48%)
     
  • Silver

    25.49
    +0.17 (+0.67%)
     
  • EUR/USD

    1.2146
    +0.0013 (+0.11%)
     
  • 10-Yr Bond

    1.0920
    -0.0050 (-0.46%)
     
  • Vix

    23.24
    -1.10 (-4.52%)
     
  • GBP/USD

    1.3653
    +0.0019 (+0.14%)
     
  • USD/JPY

    103.7430
    -0.1490 (-0.14%)
     
  • BTC-USD

    35,364.86
    -529.40 (-1.47%)
     
  • CMC Crypto 200

    702.27
    -12.92 (-1.81%)
     
  • FTSE 100

    6,712.95
    -7.70 (-0.11%)
     
  • Nikkei 225

    28,482.98
    -150.48 (-0.53%)
     

SHAREHOLDER ALERT: TILE BIIB SWI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

·3 min read

NEW YORK, NY / ACCESSWIRE / January 7, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Interface, Inc. (NASDAQ:TILE)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/interface-inc-loss-submission-form?prid=12006&wire=1
Lead Plaintiff Deadline: January 11, 2021
Class Period: March 2, 2018 - September 28, 2020

Allegations against TILE include that: (i) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (ii) consequently, Interface, inter alia, reported artificially inflated income and earnings per share ("EPS") in 2015 and 2016; (iii) Interface and certain of its employees were under investigation by the SEC with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC's investigation, and downplayed the true scope of the Company's wrongdoing and liability with respect to the SEC investigation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Biogen Inc. (NASDAQ:BIIB)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/biogen-inc-loss-submission-form?prid=12006&wire=1
Lead Plaintiff Deadline: January 12, 2021
Class Period: October 22, 2019 - November 6, 2019

Allegations against BIIB include that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

SolarWinds Corporation (NYSE:SWI)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/solarwinds-corporation-loss-submission-form?prid=12006&wire=1
Lead Plaintiff Deadline: March 5, 2021
Class Period: March 1, 2020 - December 14, 2020

Allegations against SWI include that: (1) since mid-2020, SolarWinds Orion monitoring products had a vulnerability that allowed hackers to compromise the server upon which the products ran; (2) SolarWinds' update server had an easily accessible password of ‘solarwinds123'; (3) consequently, SolarWinds' customers, including, among others, the Federal Government, Microsoft, Cisco, and Nvidia, would be vulnerable to hacks; (4) as a result, the Company would suffer significant reputational harm; and (5) as a result, Defendants' statements about SolarWinds's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/623517/SHAREHOLDER-ALERT-TILE-BIIB-SWI-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines